Scarlet Therapeutics Ltd
Alistair Irvine serves as the Founding Chief Executive Officer at Scarlet Therapeutics Ltd since August 2022 and as Managing Director at Epigenics GmbH since April 2022. Previously, Alistair held the role of Chief Business Officer at Kuros Biosciences from January 2014 to February 2023, where significant contributions included leading the due diligence for a CHF30M acquisition and streamlining development efforts through commercial evaluation. Alistair also served as Director of Business Development at Kuros Biosurgery AG from 2006 to December 2013, managing various projects and negotiations. Earlier experience includes positions at ML Laboratories plc, Cobra Therapeutics Ltd, and Therexsys Ltd, focusing on research, development of gene expression technologies, and immunotherapy. Alistair holds a BSc(Hons) in Biochemistry from The University of Edinburgh and a PhD in Molecular Biology from The University of Sheffield.
This person is not in any teams
This person is not in any offices
Scarlet Therapeutics Ltd
Scarlet Therapeutics is developing a unique platform that generates novel red blood cell-based therapeutics to potentially treat a wide range of diseases. Initially targeted at the rare metabolic diseases, hyperammonemia and hyperoxaluria, this approach could also be used more broadly to target other metabolic diseases, cancer and autoimmune diseases. These therapeutic red blood cells (tRBCs) are very similar to standard red blood cells, having many unique qualities compared to systemic administration of therapeutic protein, including pervasive reach throughout the body, a long life and the ability to carry the active proteins within the tRBC, thereby shielding them from the immune system. Born out of more than a decade of research at the University of Bristol and its learnings from the RESTORE clinical study, Scarlet also has an exclusive commercial licence for the widely used BEL-A cell line, which provides an alternative platform technology for production of red blood cells.